New research suggests that medications for obesity, particularly GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy), may also reduce alcohol consumption. The study involved 48 adults over two months, indicating that nearly 40% of participants on semaglutide reported no heavy drinking days, compared to 20% in the placebo group. However, experts caution that more extensive studies are needed to confirm these findings and assess safety for those not seeking weight loss. Teljes cikk (Euronews.com)